

**Supplement Table 3.** The baseline characteristics of studies included in the meta-analysis

First author	Publication year	Population	Age range (average)	Measures	ED assessment
Al-Ali	2015	41 men with ED, 18 men without ED	(66.4, 60.2)	cIMT	IIEF-5
Arrabal-Polo	2014	44 men with ED, 20 men without ED	(54.2, 52.4)	cIMT	IIEF-5
Averbeck	2012	34 men with ED, 18 age-matched men without ED	(59.61, 56.18)	FMD	IIEF-5
Baumhäkel	2006	71 coronary artery disease patients with ED, 48 coronary artery disease patients without ED	(64.1)	EPCs (CD133 <sup>+</sup> ); EPCs (CD34 <sup>+</sup> /KDR <sup>+</sup> )	KEED
Bhatia	2013	225 patients undergoing coronary angiography (163 had ED, 62 had no ED)	(60.4, 56.4)	FMD	IIEF-5
Bocchio	2004	45 only with ED, 25 without ED	25–67 (44.6, 45.9)	cIMT	IIEF-15
Bulbul	2022	74 men with ED, 86 age-matched men without ED	(59.8, 57.9)	ABI	IIEF-5
Caretta	2009	84 men with ED, 25 men without ED	(52.5, 47.5)	IMT cavernous	IIEF-15
Caretta	2013	77 male heart transplanted patients (50 had ED, 27 had no ED)	(64, 57.6)	IMT cavernous	IIEF-5
Chen	2016	261 men with ED, 40 men without ED	19–40	cIMT; FMD	IIEF-5
Chiurlia	2005	70 men with ED, 73 age-matched men without ED	(50.9, 50.1)	FMD; NMD	IIEF-5
Dženkevičiūtė	2013	45 caucasian men who were sexually active in a marriage or stable relationship (21 had ED, 24 had no ED)	(46.80, 48.2)	cIMT; AI	IIEF-15
Elkamshoushi	2018	15 men with ED, 15 men without ED	30–45	cIMT	IIEF-5
Esposito	2007	30 type 2 diabetic patients with ED, 20 healthy men	(57.2, 53.9)	FMD	IIEF-5
Esposito	2008	30 diabetic patients with ED, 20 nondiabetic men without ED	(56.3, 55.1)	FMD	IIEF-5
Esposito	2009	30 overweight ED patients, 30 age- and weight- matched persons without ED	(46.1, 47.5)	FMD; EPCs (CD34 <sup>+</sup> ); EPCs(CD133 <sup>+</sup> ); EPCs(KDR <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /KDR <sup>+</sup> ); EPCs(CD133 <sup>+</sup> /KDR <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> / KDR <sup>+</sup> )	IIEF-5
Foresta	2005	28 patients with ED, 22 subjects without ED	(45.3, 44.8)	EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> )	IIEF-5
Foresta	2006	26 patients with ED, 23 subjects without ED	(50.1, 47.6)	EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> )	IIEF-5
Foresta	2006	68 men with ED, 25 age-matched men without ED	(52.8, 52.5)	FMD; EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> )	IIEF-5
Foresta	2009	20 patients with ED, 15 subjects without ED	(47, 45)	EPCs(CD34 <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> / KDR <sup>+</sup> )	IIEF-15
Gerber	2015	122 patients had moderate to severe ED, 277 persons had no or mild ED	(61.7, 53.5)	FMD	IIEF-5
Guaraldi	2012	133 HIV-infected patients (79 had ED, 54 had no ED)	(50.06, 47.48)	FMD	IIEF-15
Huang	2010	52 men with ED, 22 men without ED	(29.4, 27.9)	cIMT; FMD	IIEF-5
Imai	2009	95 subjects with ED, 64 subjects without ED	(67, 54)	BAPWV	IIEF-5
Ioakeimidis	2016	180 men with ED, 50 men with negative EST who had normal erectile function	(57, 54)	FMD	IIEF-5

Supplement Table 3. Continued 1

First author	Publication year	Population	Age range (average)	Measures	ED assessment
Javaroni	2011	74 hypertensive patients with ED, 26 hypertensive patients without ED	50–70 (58.9, 60.6)	cIMT; FMD; NMD	IIEF-15
Kaiser	2004	30 men with ED, 27 age-matched men without ED	(46.6, 46.2)	cIMT; AoPWV; FMD; NMD	IIEF-15
Kakkavas	2013	43 hypertensive subjects with ED, 131 hypertensive persons without ED	(55.2, 48.8)	CFPWV	IIEF-5
Kaya	2006	32 men with ED, 25 age-matched men without ED	(55, 57)	FMD; NMD	IIEF-5
Kovac	2014	111 men with ED, 31 age-matched men without ED	(53.1, 46.8)	AI	PSV $\leq$ 25 cm/s 15 min following injection of the vasodilator
Kumagai	2018	232 subjects with ED, 85 subjects without ED	(59)	BAPWV; FAPWV	IIEF-5
Kumagai	2020	185 subjects with ED, 68 subjects without ED	(60)	AI	IIEF-5
Lahoz	2015	373 men with ED, 241 age-matched men without ED	(62.3, 59.9)	cIMT; ABI	IIEF-5
Lee	2015	208 Gout patients (51 had moderate to severe ED, 157 had none to mild ED)	(49.7, 40.8)	ABI; BAPWV	IIEF-5
Lojanapiwat	2009	41 patients with ED, 30 aged-matched persons without ED	(55.4, 55.0)	FMD	IIEF-5
Maiorino	2015	38 type 1 Caucasian diabetic patients with ED, 80 type 1 Caucasian diabetic patients without ED	(23.1, 23.4)	EPCs(CD34 <sup>+</sup> ); EPCs(CD133 <sup>+</sup> ); EPCs(KDR <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /KDR <sup>+</sup> ); EPCs(CD133 <sup>+</sup> /KDR <sup>+</sup> ); EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> /KDR <sup>+</sup> )	IIEF-5
Malpartida	2011	154 male diabetic patients (105 had ED, 49 had no ED)	(57.7, 52.1)	ABI	IIEF-15
Mazo	2006	135 patients with ED, 30 aged-matched persons without ED	(51.0, 52.1)	FMD	IIEF-15
Mulla	2021	25 men with ED, 25 age-matched men without ED	(61.20, 58.56)	cIMT	IIEF-5
Murata	2012	100 Type 2 diabetics patients (58 had ED, 42 had no ED)	(64.3, 61.8)	FMD; NMD; EPCs(CD34 <sup>+</sup> /CD133 <sup>+</sup> )	IIEF-5
Pelliccione	2012	35 men with ED, 10 men without ED	25–70	cIMT	IIEF-5
Schipilliti	2011	115 ED patients without penile vasculopathy, 50 healthy men	(49.4, 48.2)	cIMT; IMT cavernous; Femoral IMT	IIEF-15
Severo	2014	114 type 2 diabetes mellitus and hypertension patients (82 had ED, 32 had no ED)	(56.8, 56.7)	ABI	IIEF-5
Simsek	2014	150 patients with ED, 50 aged-matched persons without ED	(59.0, 58.7)	FMD	IIEF-5
Stolic	2010	73 men treated with chronic hemodialysis for over 3 months (60 had ED, 13 had no ED)	(55.06, 51.75)	cIMT	IIEF-15
Stuckey	2006	49 men with ED, 50 age-matched men without ED	40–70 (59, 56)	cIMT; FMD; NMD	IIEF-15
Uslu	2005	30 men with ED, 25 age-matched men without ED	(53.9, 52.2)	FMD; NMD	IIEF-5
Vicenzini	2008	15 men with ED, 15 men without ED	(58, 59)	cIMT	IIEF-15

Supplement Table 3. Continued 2

First author	Publication year	Population	Age range (average)	Measures	ED assessment
Vignera	2011	50 consecutive patients with ED of arterial origin, 20 healthy men	(56, 58)	IMT cavernous	IIEF-5
Vignera	2011	100 subjects with ED and Mets, 30 subjects without ED and Mets	(54.3, 52.7)	EPC (CD45 <sup>+</sup> /CD34 <sup>+</sup> /CD144 <sup>+</sup> )	IIEF-5
Vignera	2011	20 subjects only with ED, 20 healthy subjects without ED and LOH	(61.2, 61.4)	IMT cavernous; EPC (CD45 <sup>+</sup> /CD34 <sup>+</sup> /CD144 <sup>+</sup> )	IIEF-5
Vignera	2012	50 subjects with arterial ED and Mets, 20 subjects with Mets but without ED	(55, 57)	EPC (CD45 <sup>+</sup> /CD34 <sup>+</sup> /CD144 <sup>+</sup> )	IIEF-5
Vlachopoulos	2008	52 hypertensive men with vasculogenic ED, 34 age-matched HT men without ED	(61.4, 59.0)	cIMT; AI; CFPWV; FMD; NMD	IIEF-5
Yao	2012	122 patients with ED, 33 age-matched men without ED	(31.81, 29.82)	cIMT; FMD	IIEF-5
Yao	2013	192 men with ED, 33 men without ED	(29.44, 29.82)	cIMT; FMD	IIEF-5
Yavuzgil	2005	36 ED patients with cardiovascular risk, 39 no ED persons with similar cardiovascular risk	(54.4, 53.2)	FMD; NMD	IIEF-5
Yuan	2020	264 diabetic patients (188 had ED, 76 had no ED)	(49.85, 44.40)	cIMT	IIEF-5

ED: Erectile Dysfunction, cIMT: Carotid Intima–Media Thickness, IIEF: International Index of Erectile Function, FMD: Flow-Mediated Dilation, ABI: Ankle–Brachial Index, IMT: Intima–Media Thickness, NMD: Nitrate-Mediated Dilation, EPCs: Endothelial Progenitor Cells, HIV: Human Immunodeficiency Virus, EST: Exercise Stress Testing, AoPWV: Aortic Pulse Wave Velocity, CFPWV: Carotid-Femoral Pulse Wave Velocity, PSV: Peak Systolic Velocity, FAPWV: Femoral-Ankle Pulse Wave Velocity, HT: Hypertension.